Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RK-01 in Type 2 Diabetes Patients
NCT03686657Phase 2Withdrawn
- Sponsor
- ARKAY Therapeutics
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TriGlytza in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by ARKAY Therapeutics. Primary endpoints: Change in glycosylated Hemoglobin at 26 weeks and Change from baseline in acute insulin response to glucose at 26 weeks. Planned start Dec 2026; status: withdrawn.
02
Drugs
TriGlytza
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03686657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686657.